论文部分内容阅读
Hematopoietic stem cell transplantation cures aplastic anemia and has been made the treatment of choice for young patients who have suitable stem cell donors,whereas immunosuppressive therapy is the first- line treatment for most patients without suitable donors [1].
Antithymocyte globulin has been the standard immunosuppressive regimen for aplastic anemia for many years and has demonstrated a 40-50％ response rate when used alone [1,2] and a 60-70％ response rate when combined with cyclosporine [3] with 35％ relapse rate and the development of clonal diseases a significant problem to responders [4,5].
This paper reports a case of a child with acquired aplastic anemia managed with pig Antithymocyte globulin (p-ATG) and a review of literature on the effectiveness in clinical use of Antithymocyte globulin either as a monotherapy or in combination therapy with cyclosporine including or excluding human hematopoietic growth factors for the management of acquired aplastic anemia in children.
Antithymocyte globulin has been the standard immunosuppressive regimen for aplastic anemia for many years and has demonstrated a 40-50％ response rate when used alone [1,2] and a 60-70％ response rate when combined with cyclosporine [3] with 35％ relapse rate and the development of clonal diseases a significant problem to responders [4,5].
This paper reports a case of a child with acquired aplastic anemia managed with pig Antithymocyte globulin (p-ATG) and a review of literature on the effectiveness in clinical use of Antithymocyte globulin either as a monotherapy or in combination therapy with cyclosporine including or excluding human hematopoietic growth factors for the management of acquired aplastic anemia in children.